These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 8806005)

  • 1. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
    Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
    J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).
    Sato M; Zeng GQ; Rowley E; Turner CH
    Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
    Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
    Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
    Sato M; Rippy MK; Bryant HU
    FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.
    Martel C; Picard S; Richard V; Bélanger A; Labrie C; Labrie F
    J Steroid Biochem Mol Biol; 2000 Sep; 74(1-2):45-56. PubMed ID: 11074355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
    Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
    J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
    Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
    J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G; Bryant HU; Magee D; Sato M; Turner RT
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
    Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
    J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
    Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
    Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
    Helvering LM; Liu R; Kulkarni NH; Wei T; Chen P; Huang S; Lawrence F; Halladay DL; Miles RR; Ambrose EM; Sato M; Ma YL; Frolik CA; Dow ER; Bryant HU; Onyia JE
    Mol Pharmacol; 2005 Nov; 68(5):1225-38. PubMed ID: 16079270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
    Bryant HU; Dere WH
    Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
    Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.